文献速递慢阻肺

慢阻肺气道炎症:迈向精准医学

Airway inflammation in COPD: progress to precision medicine.
PubMed 文献 · Eur Respir J · 2019-08-01

本文综述慢阻肺气道炎症的异质性表型及生物标志物指导的精准治疗进展。中性粒细胞相关炎症最常见,嗜酸粒细胞相关T2炎症见于少数患者,自身免疫见于重症。皮质类固醇对嗜酸粒细胞炎症者最有效,而抗IL-5生物制剂在慢阻肺中获益有限。

要点

  • 慢阻肺气道炎症具异质性,中性粒细胞相关表型最常见。
  • 生物标志物可指导靶向抗炎治疗,皮质类固醇对嗜酸粒细胞炎症者最有效。
  • 抗IL-5生物制剂在慢阻肺中获益有限,非T2生物制剂未显获益且可能增加感染风险。

核心结论

  • 慢阻肺气道炎症存在异质性表型,生物标志物有望指导精准医学治疗。

研究设计与样本

  • 综述,总结慢阻肺气道炎症表型及生物标志物相关研究。

主要发现

  • 中性粒细胞相关慢阻肺伴炎症小体活化及T1、T17免疫是最常见表型。
  • 嗜酸粒细胞相关T2介导免疫见于少数患者,自身免疫见于更严重疾病。
  • 皮质类固醇对嗜酸粒细胞炎症证据者最有效。
  • 抗IL-5生物制剂在慢阻肺中获益有限,相同嗜酸粒细胞炎症强度下获益小于重症哮喘。
  • 非T2生物制剂未显获益,部分增加感染风险,提示中性粒细胞炎症可能由细菌定植和菌群失调驱动。

临床怎么用

  • 临床可依据生物标志物识别嗜酸粒细胞炎症表型,指导皮质类固醇使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic obstructive pulmonary disease (COPD) is a significant cause of morbidity and mortality worldwide, and its prevalence is increasing. Airway inflammation is a consistent feature of COPD and is implicated in the pathogenesis and progression of COPD, but anti-inflammatory therapy is not first-line treatment. The inflammation has many guises and phenotyping this heterogeneity has revealed different patterns. Neutrophil-associated COPD with activation of the inflammasome, T1 and T17 immunity is the most common phenotype with eosinophil-associated T2-mediated immunity in a minority and autoimmunity observed in more severe disease. Biomarkers have enabled targeted anti-inflammatory strategies and revealed that corticosteroids are most effective in those with evidence of eosinophilic inflammation, whereas, in contrast to severe asthma, response to anti-interleukin-5 biologicals in COPD has been disappointing, with smaller benefits for the same intensity of eosinophilic inflammation questioning its role in COPD. Biological therapies beyond T2-mediated inflammation have not demonstrated benefit and in some cases increased risk of infection, suggesting that neutrophilic inflammation and inflammasome activation might be largely driven by bacterial colonisation and dysbiosis. Herein we describe current and future biomarker approaches to assess inflammation in COPD and how this might reveal tractable approaches to precision medicine and unmask important host-environment interactions leading to airway inflammation.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Brightling C, Greening N. Airway inflammation in COPD: progress to precision medicine. Eur Respir J. 2019. PMID: 31073084. doi:10.1183/13993003.00651-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。